SG10201507845PA - Antibodies binding to an intracellular prl-1 or prl-3 polypeptide - Google Patents

Antibodies binding to an intracellular prl-1 or prl-3 polypeptide

Info

Publication number
SG10201507845PA
SG10201507845PA SG10201507845PA SG10201507845PA SG10201507845PA SG 10201507845P A SG10201507845P A SG 10201507845PA SG 10201507845P A SG10201507845P A SG 10201507845PA SG 10201507845P A SG10201507845P A SG 10201507845PA SG 10201507845P A SG10201507845P A SG 10201507845PA
Authority
SG
Singapore
Prior art keywords
prl
polypeptide
intracellular
antibodies binding
antibodies
Prior art date
Application number
SG10201507845PA
Inventor
Ql Zeng
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Publication of SG10201507845PA publication Critical patent/SG10201507845PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
SG10201507845PA 2007-05-03 2008-05-03 Antibodies binding to an intracellular prl-1 or prl-3 polypeptide SG10201507845PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92420107P 2007-05-03 2007-05-03
US6422908P 2008-02-22 2008-02-22

Publications (1)

Publication Number Publication Date
SG10201507845PA true SG10201507845PA (en) 2015-10-29

Family

ID=39720285

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201507845PA SG10201507845PA (en) 2007-05-03 2008-05-03 Antibodies binding to an intracellular prl-1 or prl-3 polypeptide

Country Status (12)

Country Link
US (3) US8715674B2 (en)
EP (3) EP2150276B1 (en)
JP (1) JP2010530735A (en)
CN (3) CN101820910B (en)
AU (1) AU2008246368A1 (en)
CA (1) CA2685954A1 (en)
DK (2) DK2150276T3 (en)
ES (1) ES2846400T3 (en)
GB (1) GB2462048B (en)
HK (1) HK1252633A1 (en)
SG (1) SG10201507845PA (en)
WO (1) WO2008136774A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2685954A1 (en) 2007-05-03 2008-11-13 Agency For Science, Technology And Research Antibodies binding to an intracellular prl-1 or prl-3 polypeptide
CN102753191B (en) * 2009-11-30 2016-08-24 新加坡科技研究局 By the cancer that antibody therapy or vaccine therapy are relevant to intracellular cancer protein with prevention
CN108434440B (en) * 2011-09-06 2022-08-23 新加坡科技研究局 Polypeptide vaccine
US20150329643A1 (en) 2012-11-16 2015-11-19 Albert Einstein College Of Medicine Of Yeshiva University Identification and use of new tumor-promoting gene in hematological malignancies
CN104650187B (en) * 2013-11-19 2017-11-24 中国科学院苏州纳米技术与纳米仿生研究所 Polypeptide, its production method and purposes
JP6343017B2 (en) * 2014-02-07 2018-06-13 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ PRL-3 as a biomarker for cancer prognosis and target for therapy
CN110684845A (en) * 2014-03-19 2020-01-14 上海吉凯基因化学技术有限公司 Application of human PTP4A3 gene and related drugs thereof
US9631024B2 (en) 2014-06-23 2017-04-25 Bionomics, Inc. Antibodies that bind LGR4, their use in inhibiting neoplastic cells and in treating tumors
CN104087663B (en) * 2014-07-02 2016-04-13 中山大学 The application of PRL-1 gene in preparation diagnosis and/or Hepatoma therapy product
SG10201404895XA (en) * 2014-08-13 2016-03-30 Agency Science Tech & Res Diagnosis
US11331388B1 (en) * 2015-09-03 2022-05-17 La Jolla Institute For Allergy And Immunology PTP4A1 as a therapeutic target for fibrotic diseases and disorders including systemic sclerosis
WO2017070567A1 (en) * 2015-10-21 2017-04-27 The Research Foundation For The State University Of New York Klebsiella pneumoniae antibodies and methods to treat klebsiella pneumoniae infections
CL2016000164A1 (en) * 2016-01-21 2016-07-29 Pontificia Universidad Católica De Chile Monoclonal antibodies specific for the human adenovirus piii antigen (adv), produced and secreted by cellular hybridomas, useful for the detection and diagnosis of adv caused infection.
SG11201811068YA (en) * 2016-06-14 2019-01-30 Agency Science Tech & Res Prl3 antibody

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (en) 1971-02-10 1977-09-15 Organon Nv METHOD FOR THE DETERMINATION AND DETERMINATION OF SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES.
NL154598B (en) 1970-11-10 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
NL154599B (en) 1970-12-28 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES, AND TEST PACKAGING.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (en) 1972-05-11 1983-06-01 Akzo Nv METHOD FOR DETERMINING AND DETERMINING BITES AND TEST PACKAGING.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
CA1203164A (en) 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
GB9001641D0 (en) 1990-01-24 1990-03-21 Imp Cancer Res Tech Compounds
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
GB9402857D0 (en) 1994-02-15 1994-04-06 Isis Innovation Targeting gene therapy
WO1995030018A2 (en) 1994-04-29 1995-11-09 Immuno Aktiengesellschaft Recombinant poxviruses with foreign polynucleotides in essential regions
CA2303227A1 (en) * 1997-09-19 1999-03-25 Incyte Pharmaceuticals, Inc. Human prl-1 phosphatase
US6100090A (en) 1999-06-25 2000-08-08 Isis Pharmaceuticals Inc. Antisense inhibition of PI3K p85 expression
AU2002362646A1 (en) * 2001-10-09 2003-04-22 The Johns Hopkins University A phosphatase associated with metastasis
US20050287644A1 (en) * 2004-05-14 2005-12-29 Genesis Biotech Inc. Methods for producing and culturing rabbit-mouse hybridomas and monoclonal antibodies secreted by rabbit-mouse hybridomas
WO2006091326A1 (en) * 2005-01-28 2006-08-31 Attogen Inc. Anti-prl-3 antibodies and methods of use thereof
CA2685954A1 (en) * 2007-05-03 2008-11-13 Agency For Science, Technology And Research Antibodies binding to an intracellular prl-1 or prl-3 polypeptide
US8715941B2 (en) * 2007-11-16 2014-05-06 Arca Biopharma, Inc. Antibodies to LRP6
BR112013002940A2 (en) * 2010-08-13 2019-09-24 Baylor Res Institute new vaccine adjuvants based on targeting adjuvants for antibodies directly to antigen presenting cells
WO2012129227A1 (en) * 2011-03-22 2012-09-27 Baylor Research Institute Dendritic cells (dcs) targeting for tuberculosis (tb) vaccine
MX2014005358A (en) * 2011-11-03 2014-09-12 Tolera Therapeutics Inc Antibody and methods for selective inhibition of t-cell responses.

Also Published As

Publication number Publication date
CN101820910A (en) 2010-09-01
EP2529754A1 (en) 2012-12-05
DK2150276T3 (en) 2014-08-18
US20110206657A1 (en) 2011-08-25
EP2150276A1 (en) 2010-02-10
EP3360571B1 (en) 2020-12-16
CN107098970A (en) 2017-08-29
WO2008136774A1 (en) 2008-11-13
US10174126B2 (en) 2019-01-08
US20140286937A1 (en) 2014-09-25
US20170008972A1 (en) 2017-01-12
AU2008246368A1 (en) 2008-11-13
CA2685954A1 (en) 2008-11-13
HK1252633A1 (en) 2019-05-31
CN101820910B (en) 2014-08-06
JP2010530735A (en) 2010-09-16
GB2462048B (en) 2012-03-21
US9321845B2 (en) 2016-04-26
US8715674B2 (en) 2014-05-06
EP2150276B1 (en) 2014-05-21
ES2846400T3 (en) 2021-07-28
DK3360571T3 (en) 2021-01-04
GB0921121D0 (en) 2010-01-20
WO2008136774A8 (en) 2009-07-23
GB2462048A (en) 2010-01-27
CN102847148A (en) 2013-01-02
CN107098970B (en) 2021-11-23
EP3360571A1 (en) 2018-08-15

Similar Documents

Publication Publication Date Title
HK1252633A1 (en) Antibodies binding to an intracellular prl-1 or prl-3 polypeptide
HRP20181616T1 (en) Fully human anti-vap-1 monoclonal antibodies
HK1220706A1 (en) Specific binding proteins and uses thereof
IL232008A (en) Isolated alpha-4beta-7 heterodimer specific antigen binding protein and various aspects related thereto
ZA201004133B (en) Antigen binding proteins
HK1200320A1 (en) Il-17 binding proteins il-17
HK1170506A1 (en) Bispecific antigen binding proteins
ZA201003578B (en) Wise binding antibodies and epitopes
IL225397A0 (en) Antibodies binding human collagen ii
EP2481754A4 (en) Specific binding proteins and uses thereof
IL236236A (en) Fam26f polypeptide antibodies
IL216261A0 (en) IL-13 binding protein
IL208188A0 (en) Compositions comprising antibodies or antibody fragments
EP2484694A4 (en) Monoclonal antibody against human hig-1 polypeptide
IL182717A0 (en) Antibodies to interferon - ??/?? binding protein
EP2540742A4 (en) Anti-cyr61 protein monoclonal antibodies and uses thereof